Holen Sie sich die Stockscreener-App
42.65
1.20%
-0.52
Handel nachbörslich:
41.89
-0.76
-1.78%
Schlusskurs vom Vortag:
$43.17
Offen:
$43.65
24-Stunden-Volumen:
1.56M
Relative Volume:
0.57
Marktkapitalisierung:
$5.66B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-237.54M
KGV:
-17.04
EPS:
-2.5033
Netto-Cashflow:
$-145.05M
1W Leistung:
-0.35%
1M Leistung:
-5.12%
6M Leistung:
+143.99%
1J Leistung:
+0.00%
1-Tages-Spanne:
$41.73
$45.42
1-Wochen-Bereich:
$41.57
$45.42
52-Wochen-Spanne:
$14.62
$49.20
Definium Therapeutics Inc Stock (DFTX) Company Profile
Firmenname
Definium Therapeutics Inc
Sektor
Branche
Telefon
212-220-6633
Adresse
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
42.65 | 5.73B | 0 | -237.54M | -145.05M | -2.5033 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-17 | Eingeleitet | Stifel | Buy |
| 2026-04-10 | Eingeleitet | Piper Sandler | Overweight |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-01-30 | Eingeleitet | Jefferies | Buy |
| 2025-10-13 | Eingeleitet | Needham | Buy |
| 2025-08-04 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-01-28 | Eingeleitet | Evercore ISI | Outperform |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-07-24 | Eingeleitet | ROTH MKM | Buy |
| 2024-05-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-05 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-12-09 | Fortgesetzt | ROTH Capital | Buy |
| 2022-11-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-26 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Eingeleitet | ROTH Capital | Buy |
| 2021-06-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Definium Therapeutics Inc Aktie (DFTX) Neueste Nachrichten
DFTX Initiates Coverage On Wells Fargo -- Rating Set to Overweig - GuruFocus
Wells Fargo Initiates Definium Therapeutics at Overweight - marketscreener.com
DFTX Reiterated by Piper Sandler -- Price Target Raised to $73.0 - GuruFocus
Piper Sandler raises Definium stock price target on DT120 outlook By Investing.com - Investing.com South Africa
Piper Sandler raises Definium stock price target on DT120 outlook - Investing.com UK
Piper Sandler Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $73 - Moomoo
DEFINIUM THERAPEUTICS INC : PIPER SANDLER RAISES TARGET PRICE TO $73 FROM $48 - Bitget
Definium Therapeutics (DFTX) Highlights GAD Care Gaps, Is The Stock Already Overvalued? - Yahoo Finance
How New GAD Treatment Gap Data At Definium Therapeutics (DFTX) Has Changed Its Investment Story - Yahoo Finance
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
Definium Therapeutics Inc. (DFTX) Fundamental & Financial Data - Stocktwits
Definium Therapeutics Announces New Employee Inducement Grants - The Globe and Mail
Definium Therapeutics, Inc. (DFTX) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Why Is GH Research Stock Trading Higher on Thursday? - Benzinga
Analysts Are Bullish on Top Healthcare Stocks: Staar Surgical (STAA), Definium Therapeutics (DFTX) - The Globe and Mail
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology - Times Argus
Definium Therapeutics Inc. (DFTX) News, Articles, Events & Latest Updates - Stocktwits
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $63 - Moomoo
Is Definium Therapeutics, Inc. (DFTX) Stock a Biotech Opportunity After Positive DT120 Depression Trial Data? - Yahoo Finance
Definium Therapeutics (DFTX) Could Be 30% Overvalued After New GAD Study - Sahm
Wall Street Analysts Think Definium Therapeutics, Inc. (DFTX) Could Surge 32.42%: Read This Before Placing a Bet - Yahoo Finance
Definium Therapeutics, Inc. Announces Results from New Healthcare Claims Study of Treatment Patterns of Newly Diagnosed and Established Gad Patients, Including Pharmacotherapy Use, Discontinuation, Switching and Treatment Progression - marketscreener.com
Why is Definium Therapeutics stock rallying today? By Investing.com - Investing.com Nigeria
More Than Half of Newly Diagnosed GAD Patients Stopped Therapy - Stock Titan
Definium Therapeutics eyes key DT-120 depression data, advances anxiety program - MSN
DFTX Inc. Stock (DFTX) Opinions on Phase 3 Results and Offering - Moomoo
Why is Definium Therapeutics stock rallying today? - Investing.com
Definium Therapeutics (DFTX) Following Russell Index Removal And The Fair Value Debate - Sahm
Stifel Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $60 - Moomoo
Stifel raises Definium Therapeutics price target on MDD data By Investing.com - Investing.com Nigeria
Stifel raises Definium Therapeutics price target on MDD data - Investing.com
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering - AOL.com
Earnings call transcript: Definium’s Q1 2026 EPS miss overshadows strategic advances - Investing.com
Positive Phase 3 DT120 ODT Results in Depression Could Be A Game Changer For Definium Therapeutics (DFTX) - Sahm
Definium earnings on deck as pivotal psychedelic trial data looms By Investing.com - Investing.com India
DFTXDefinium Therapeutics Inc Volatility & Greeks - Finviz
Finanzdaten der Definium Therapeutics Inc-Aktie (DFTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):